MobileNet-V2 /IFHO model for Accurate Detection of early-stage diabetic retinopathy.

Researchers

Journal

Modalities

Models

Abstract

Diabetic retinopathy is a serious eye disease that may lead to loss of vision if it is not treated. Early detection is crucial in preventing further vision impairment and enabling timely interventions. Despite notable advancements in AI-based methods for detecting diabetic retinopathy, researchers are still striving to enhance the efficiency of these techniques. Therefore, obtaining an efficient technique in this field is essential. In this research, a new strategy has been proposed to improve the detection of diabetic retinopathy by increasing the accuracy of diagnosis and identifying cases in the initial stages. To achieve this, it has been proposed to integrate the MobileNet-V2 deep learning-based neural network with Improved Fire Hawk Optimizer (IFHO). The MobileNet-V2 network has been renowned for its efficiency and accuracy in image classification tasks, making it a suitable candidate for diabetic retinopathy detection. By combining it with the IFHO, the feature selection process has been optimized, which is essential for identifying relevant patterns and abnormalities related to diabetic retinopathy. The Diabetic Retinopathy 2015 dataset has been used to evaluate the effectiveness of the MobileNet-V2/IFHO model. The study results indicate that the DRMNV2/IFHO model consistently outperforms other methods in terms of precision, accuracy, and recall. Specifically, the model achieves an average precision of 97.521 %, accuracy of 96.986 %, and recall of 98.543 %. Moreover, when compared to advanced techniques, the DRMNV2/IFHO model demonstrates superior performance in specificity, F1-score, and AUC, with average values of 97.233 %, 93.8 %, and 0.927, respectively. These results underscore the potential of the DRMNV2/IFHO model as a valuable tool for improving the accuracy and efficiency of DR diagnosis. Nevertheless, additional validation and testing on larger datasets are required to verify the model’s effectiveness and robustness in real-world clinical scenarios.© 2024 The Authors.